Non-Hodgkin Lymphoma

Guenther Koehne, MD, PhD, discusses the real-life study of CAR T-cell agents axicabtagene ciloleucel vs tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma.

A new drug application seeking the approval of valemetostat tosylate for use in the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma has been submitted to the Japanese Ministry of Health, Labour, and Welfare.

Zandelisib demonstrated significant activity and an encouraging preliminary safety profile in patients with relapsed/refractory follicular lymphoma who have received at least 2 prior systemic therapies.

Parsaclisib, an investigational highly selective phosphatidylinositol 3-kinase δ inhibitor, demonstrated rapid and durable responses as monotherapy with an acceptable safety profile in patients with relapsed/refractory follicular lymphoma in the phase 2 CITADEL-203 study.

Patients with relapsed or refractory large B-cell lymphoma experienced better quality of life when they received second-line treatment with lisocabtagene maraleucel vs standard of care.

The addition of tafasitamab and lenalidomide to rituximab, cyclophosphamide, doxorubicin, and prednisone demonstrated increased but generally comparable adverse effects and higher, prolonged, and deeper responses vs the combination of tafasitamab and R-CHOP alone in patients with previously untreated diffuse large B-cell lymphoma.

YTB323, a novel, autologous CD19-directed CAR-T cell therapy, displayed a favorable safety profile and efficacy across multiple dose levels in adult patients with relapsed/refractory diffuse large b-cell lymphoma.

Frontline treatment with axicabtagene ciloleucel demonstrated rapid and durable responses in patients with high-risk large B-cell lymphoma.

The addition of polatuzumab vedotin-piiq to R-CHP led to a 27% reduction in the risk of progression or death vs R-CHOP in patients with previously untreated, intermediate- and high-risk diffuse large B-cell lymphoma.

As second-line treatment, tisagenlecleucel failed to demonstrate an event-free survival advantage compared with standard of care platinum-based chemotherapy followed by autologous stem cell transplant or additional chemotherapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Treatment with lisocabtagene maraleucel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphomas.

Naratuximab emtansine plus rituximab had promising response rates while also improving patient well-being when used to treat diffuse relapsed/refractory large B-cell lymphoma and other non-Hodgkin B-cell lymphomas.

Tisagenlecleucel demonstrated encouraging real-world efficacy and a favorable safety profile that was consistent with findings from the pivotal phase 2 JULIET trial in patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma.

The combination of tafasitamab and lenalidomide prolonged median overall survival compared with other standard options for autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.

Sattva S. Neelapu, MD, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma. 

Tisagenlecleucel produced a high overall response rate and complete response rate in adult patients with relapsed/refractory follicular lymphoma who had received 2 or more prior lines of therapy, according to results from an extended follow-up analysis of patients with at least 12 months of follow-up of the phase 2 ELARA trial.

Axicabtagene ciloleucel induced high response rates and improved survival in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma, according to updated data from the phase 2 ZUMA-5 trial.

Fixed-duration treatment with the bispecific antibody mosunetuzumab induced deep and durable responses with favorable tolerability in heavily pretreated patients with relapsed or refractory follicular lymphoma, meeting the primary end point of the ongoing phase 1/2b GO29781 trial.

Lisocabtagene maraleucel demonstrated statistically and clinically meaningful improvement in event-free survival compared with the standard of care as a second-line therapy in patients with relapsed or refractory large B-cell lymphoma.

Two new studies by Yale Cancer Center reveal the structure of the molecule known as anaplastic lymphoma kinase, which is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors.

Not only is the 2021 ASH Annual Meeting bursting with more than 5000 abstracts unveiling pivotal data across a range of hematologic malignancies and disorders, but the conference will be held as a hybrid format after going fully virtual in 2020.

Secura Bio, Inc. has decided to voluntarily withdraw the indication of duvelisib for use in patients with relapsed or refractory follicular lymphoma following at least 2 previous systemic therapies.

Meghan Thompson, MD, discusses the results from the use of pirtobrutinib in the phase 1/2 BRUIN study, as well as upcoming research efforts in the population of patients with Richter transformation.

Lisocabtagene maraleucel significantly prolonged event-free survival and progression-free survival and improved complete responses when used in the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.

Alexandra Stefanovic, MD, discusses the emergence of umbralisib in marginal zone lymphoma and follicular lymphoma.